Core Viewpoint - The Hong Kong innovative drug sector is experiencing a downturn, with significant declines in major stocks such as Hengrui Medicine and Innovent Biologics, leading to a drop in the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index below its six-month moving average [1][5]. Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) is tracking the index and has seen a widening premium in the market, indicating strong buying interest. Over the past ten days, the ETF has attracted over 184 million yuan in capital [3][5]. - The ETF's underlying index has lost volume and breached the six-month moving average, necessitating close monitoring of its future performance. Investors are advised to wait for a clear signal of a bottom before re-entering the market [5]. Fundamental Analysis - There are no significant negative factors affecting the innovative drug sector, with a continuation of high certainty in industry trends. A new round of the "National Science and Technology Major Project for Innovative Drug R&D" has been launched, aiming to establish a self-controlled national drug innovation system by 2035 [5]. - Historically, during the Federal Reserve's rate-cutting cycles, the valuation of Hong Kong innovative drug assets tends to expand, benefiting from a favorable liquidity environment for financing and R&D investments. The Fedwatch data indicates a high probability of two more rate cuts this year [5]. ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) exclusively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, which is composed entirely of innovative drug R&D companies, with over 70% of its holdings in large-cap leaders [6]. - As of the end of September, the ETF has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [6][7]. - The ETF has a total fund size of 1.806 billion yuan and an average daily trading volume of 493 million yuan since its inception, making it the largest and most liquid ETF in its category [7].

伴随公募三季报密集披露，绩优基金经理持仓动向备受市场关注。 10月27日，鹏华碳中和主题、永赢医药创新智选、中航机遇领航、安信新回报等多只"翻倍基"披露三季报。其中，"翻倍基"大多布局了人工智能、算力、 创新药等近年来比较热门的赛道。在前十大重仓股中，还涌现出多只"大牛股"。 【导读】三季报密集披露，绩优基金调仓曝光 记者注意到，伴随业绩表现亮眼，中航机遇领航三季度末规模达132.31亿元，较二季度末猛增近12倍。永赢医药创新智选三季度末规模为78.29亿元，较二 季度末增长157.28%。 韩浩：AI算力的成长空间依然很高 根据中航机遇领航最新发布的三季报，该基金主要布局AI算力产业链。截至三季度末，该基金股票仓位为88.56%。 具体来看，英维克、新易盛、中际旭创、胜宏科技前四大重仓股持有市值均在12亿元以上。截至发稿，这四只股票今年以来股价分别涨超148%、391%、 315%、682%。 前十大重仓股中，有多达7只个股被大幅度增持。其中，该基金对沪电股份的持仓股数较二季度末增加669.13%，增持幅度尤为显著。天孚通信、胜宏科 技也增持幅度超500%。此外，英维克、中际旭创和新易盛的增持幅度均超过30 ...

Group 1 - The core focus of several fund managers in Q3 has been on PCB leading stocks, particularly East Mountain Precision, with notable increases in holdings by prominent funds [2][3] - The fund "Yongying Technology Smart Select" has shown significant performance, with a year-to-date return exceeding 200%, and has heavily invested in the PCB sector and optical module leaders [3][5] - Fund managers have expressed confidence in the A-share market, highlighting the potential for further asset allocation towards equity due to favorable domestic fiscal and monetary policies [10][11] Group 2 - Fund managers have adjusted their portfolios, with some reducing holdings in optical module leaders while increasing investments in the robotics industry [6][7] - The "Yongying Technology Smart Select" fund has seen its net asset value growth rate approach 100%, leading to a substantial increase in fund size from 11.66 billion to 115.21 billion [12] - There is a growing interest in Hong Kong stocks, with funds increasing their positions in companies like Alibaba and various biotech firms, reflecting a dual focus on technology and recovery sectors [9]

Group 1: Market Performance and Opportunities - The MSCI China Healthcare Index has increased by 58.6% year-to-date, outperforming the MSCI China Index which rose by 24.2% [1] - The recent slight pullback in the healthcare sector (10% decline in MSCI China Healthcare Index since October) presents a buying opportunity [1] - The recovery in capital market financing and the increase in overseas transactions for innovative drugs indicate a rebound in domestic innovative drug R&D demand [1] Group 2: Clinical Data and Drug Development - SKB264 is the only drug showing statistically significant overall survival (OS) in a Phase III trial for EGFR-TKI resistant NSCLC, with a hazard ratio (HR) of 0.56 compared to chemotherapy [2] - Ivonescimab demonstrated a median progression-free survival (mPFS) of 11.1 months in first-line sqNSCLC, outperforming the comparator at 6.9 months (HR=0.60) [2] - The uORR for drug 707 in first-line colorectal cancer reached 82.6%, with a cORR of 65.2%, indicating strong efficacy [2] Group 3: Strategic Collaborations and Future Outlook - The company suggests focusing on the clinical advancement of authorized pipelines overseas, as this has a higher certainty of success and can act as a catalyst for stock price increases [3] - The strategic collaboration between Innovent Biologics and Takeda for IBI363 involves shared global R&D costs and commercial rights, reflecting confidence in the drug and commitment to global strategy [3] - Pfizer is expected to announce overseas clinical plans for drug 707 within the year, with a focus on its combination with multiple ADC products [3]

Group 1 - The MSCI China Healthcare Index has increased by 58.6% since the beginning of 2025, outperforming the MSCI China Index by 24.2% [1] - The recent slight pullback in the healthcare sector (10% since October) presents a buying opportunity, driven by a recovery in capital market financing and an increase in the scale of innovative drug exports [1] - The CXO industry is expected to see performance recovery in the second half of 2025 due to the anticipated interest rate cuts in the U.S. [1] Group 2 - Significant clinical data was released at the ESMO conference, highlighting key drugs such as SKB264, which shows statistical significance in overall survival for NSCLC patients resistant to EGFR-TKI [2] - The mPFS for lvonescimab in first-line sqNSCLC was reported at 11.1 months, compared to 6.9 months for the control group [2] - The uORR for drug 707 from 三生制药 in first-line colorectal cancer reached 82.6%, indicating strong efficacy [2] Group 3 - The impact of business development (BD) on stock prices is diminishing, prompting a focus on the clinical advancement of authorized pipelines overseas [3] - 信达生物 has entered a global strategic partnership with Takeda for IBI363, sharing 40% of global R&D costs and U.S. commercial rights, reflecting confidence in the drug and commitment to globalization [3] - The company anticipates that clinical progress will serve as a catalyst for stock price increases, with most value realization dependent on successful commercialization rather than upfront payments from licensing deals [3]

Investment Rating - The report rates the pharmaceutical industry as "Positive" [1][33] Core Viewpoints - The source of innovation in the pharmaceutical industry is improving, and short-term fluctuations do not change long-term value. The ESMO 2025 conference highlighted 23 "Late-Breaking Abstracts" led by Chinese scholars, with 3 significant results presented at the highest academic level, indicating China's growing position in global pharmaceutical innovation [5][26] - Domestic innovative drugs are showing competitive clinical data, with several products demonstrating global competitiveness. For instance, the sac-TMT from Kelun Biotech is expected to be a strong competitor for EGFR mutation NSCLC after EGFR-TKI resistance [5][6] - Investment suggestions focus on shifting attention from "expectations" to "realization" of clinical data and commercialization. Key directions include companies with validated R&D and commercialization capabilities, those entering performance release periods, and those with excellent clinical data pipelines [5][27] Summary by Sections Section 1: Kelun Biotech - The sac-TMT is expected to be a strong competitor for EGFR mutation NSCLC after EGFR-TKI treatment failure, with significant clinical data presented at ESMO 2025 [6][8] Section 2: Kangfang Biotech - The HARMONi-6 study results met expectations, showing significant PFS benefits compared to the control group, with ongoing overseas clinical research updates anticipated [9][10] Section 3: Basestone Pharmaceuticals - The CS2009's efficacy and safety have been preliminarily validated, showing promise as a next-generation I-O therapy competitor [12][14] Section 4: Shouyao Holdings - The SY-5007 demonstrated significant efficacy advantages in RET fusion-positive NSCLC patients, with a low treatment-related discontinuation rate [16][18] Section 5: Jinfang Pharmaceuticals - The GFH375 showed promising efficacy in treating KRAS G12D mutation pancreatic cancer, with a notable objective response rate [19][21] Section 6: Aosaikang - The ASKB589 combined with chemotherapy and PD-1 inhibitors showed significant survival benefits in advanced gastric cancer patients [23][25]

Core Viewpoint - The innovation drug sector in China is experiencing significant growth, driven by policy support, innovation upgrades, and normalization of overseas business development, indicating a period of high prosperity for the industry [5]. Group 1: Market Performance - As of October 27, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Innovation Drug Index rose by 2.50%, with notable increases in constituent stocks such as Ailis (up 5.76%) and ZhiXiang JinTai (up 5.63%) [1]. - The Huatai-PineBridge Innovation Drug ETF (589120) increased by 2.67%, with a latest price of 0.89 yuan, and has seen a cumulative increase of 1.06% since the beginning of October [1]. - The ETF recorded a turnover rate of 4.12% and a trading volume of 15.2063 million yuan, with an average daily trading volume of 24.6571 million yuan over the past year [1]. Group 2: Financial Performance - WuXi AppTec reported a net profit of 3.515 billion yuan for Q3 2025, a year-on-year increase of 53.27%, and a total net profit of 12.076 billion yuan for the first three quarters, up 84.84% year-on-year [3]. - The growth in profits is attributed to the company's focus on the CRDMO business model, increased operational efficiency, and gains from the sale of shares in WuXi XDC Cayman Inc. [3]. Group 3: Industry Developments - The 2025 European Society for Medical Oncology (ESMO) annual meeting showcased significant breakthroughs in Chinese innovative drug research, with multiple clinical data points reaching international leading levels [4]. - Notable presentations included CanSino Biologics' results on the efficacy of Ivosidenib in advanced squamous non-small cell lung cancer and Rongchang Biologics' RC48-C016 study in HER2+ urothelial carcinoma, which achieved significant benefits in progression-free survival (PFS) and overall survival (OS) [4]. - The Federal Reserve's initiation of a rate-cutting cycle is expected to benefit innovative assets, particularly in the pharmaceutical sector, as historical trends show that innovative assets tend to outperform during such periods [4].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it highlights significant developments that may influence future ratings [1]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 0.58%, underperforming compared to the Wind All A index (3.47%) and the CSI 300 index (3.24%) [2][7]. - A major strategic collaboration was announced between Innovent Biologics and Takeda Pharmaceutical, with a total deal value potentially reaching $11.4 billion, including an upfront payment of $1.2 billion and milestone payments of up to $10.2 billion [2][10]. - The report emphasizes the importance of the upcoming commercial insurance innovative drug directory, which is expected to be released soon, and suggests monitoring the companies that will be included [2][11]. Weekly Market Review - The pharmaceutical and biotechnology sector's performance was mixed, with medical research outsourcing (5.47%), offline pharmacies (2.99%), and pharmaceutical distribution (1.97%) leading the gains, while other biological products (-1.91%), traditional Chinese medicine (-0.85%), and chemical preparations (-0.41%) lagged behind [2][7]. - Notable stock performances included Teva Pharmaceutical (22.3%), Bid Pharma (18.9%), and *ST Jingfeng (16.6%) as top gainers, while Tuo Jing Life (-18.6%), Xin Nuo Wei (-17.5%), and Shuo Tai Shen (-14.9%) were the biggest losers [2][10]. Industry News and Key Company Announcements - Innovent Biologics announced a significant global strategic partnership with Takeda to accelerate the development of new therapies, including three key drug candidates [2][10]. - Kangfang Biologics' AK112 injection has been proposed for inclusion in breakthrough therapy designation for treating triple-negative breast cancer [2][11]. - Summit Therapeutics announced a $500 million private placement to fund the clinical development of its drug candidate [2][11]. - Ipsen and ImCheck Therapeutics reached a final agreement for a €1 billion acquisition focused on a first-in-class monoclonal antibody for acute myeloid leukemia [2][13]. - Moderna decided to terminate the development of its CMV mRNA vaccine after failing to meet primary endpoints in a Phase III trial [2][13].

Investment Rating - The report maintains an "Overweight" investment rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The report highlights that the 2025 ESMO conference showcased significant advancements from Chinese innovative drug companies, marking a shift from being followers to leaders in the global market [19][22]. - The A-share pharmaceutical index has shown a year-to-date increase of 19.54%, with a weekly increase of 0.58%, while the Hang Seng Biotechnology Index has surged by 81.15% year-to-date [9]. - Key sub-sectors showing positive performance include medical services (+3.94%), pharmaceutical commerce (+2.27%), and medical devices (+0.89%), while chemical pharmaceuticals and traditional Chinese medicine experienced declines [9]. Summary by Sections Industry Trends - The report notes that the Chinese pharmaceutical sector is entering a harvest period, with a significant increase in the number and quality of research presented at the ESMO conference [16][19]. - The report emphasizes the successful approval of innovative drugs, such as Boehringer Ingelheim's treatment for pulmonary fibrosis and Novartis' drug for polymyalgia rheumatica, which have achieved significant clinical milestones [4]. Research and Development Progress - The report details several groundbreaking studies that have the potential to change existing treatment paradigms, including studies on innovative drugs and ADCs (antibody-drug conjugates) [4][22]. - Specific companies are highlighted for their promising research pipelines, including Innovent Biologics, Rongchang Biologics, and others, which have made significant contributions to the field [12][22]. Market Performance - The report provides a detailed analysis of stock performance within the pharmaceutical sector, noting that certain stocks, such as Teva Pharmaceutical and ST Rong Control, have seen significant weekly gains [9][11]. - The report suggests a ranking of favored sub-sectors for investment, with innovative drugs, research services, and CXO services at the top of the list [10][12]. Recommendations - The report recommends specific companies for investment based on their performance and potential, including Hengrui Medicine, WuXi AppTec, and others across various sub-sectors [11][12].

Investment Rating - The report maintains a rating of "Outperform" for the pharmaceutical and biotechnology sector, indicating a positive outlook compared to the broader market [7]. Core Insights - The overseas CXO industry is entering a phase of accelerated recovery, with significant investment opportunities in domestic and foreign demand-driven CXO companies. Key companies to focus on include WuXi AppTec, WuXi Biologics, and others [4][17]. - The macro-level investment trends show a recovery in BD transactions and mergers, while PE/VC financing is still lagging behind. The global biopharmaceutical financing amount for Q1-Q3 2025 was $19.26 billion, down 13.8% year-on-year, but close to the $20.71 billion level of the same period in 2023 [17][21]. - The micro-level performance of major overseas CXO companies indicates a positive trend, with new molecular businesses maintaining high growth rates. Companies are generally optimistic about their annual performance guidance [21][25]. Summary by Sections Weekly Market Review - The CITIC Pharmaceutical Index increased by 0.6% from October 20 to October 24, 2025, underperforming the CSI 300 Index by 2.7 percentage points. Year-to-date, the CITIC Pharmaceutical Biotech Index has risen by 20.5%, outperforming the CSI 300 Index by 2.1 percentage points [3][32]. - The top-performing stocks this week included Teva Pharmaceutical (+22.3%), Bid Pharma (+18.9%), and others, indicating a strong performance in the CXO sector [3][47]. Investment Opportunities in CXO - The report emphasizes the importance of strategic allocation in the overseas CXO sector, highlighting the recovery in demand and performance of companies involved in new molecular businesses. The report suggests focusing on companies like WuXi AppTec and others [4][17]. - The performance of major overseas CXO companies in Q2 2025 showed that peptide CDMO outperformed other segments, with companies adjusting their annual performance guidance upwards [21][25]. Short-term Investment Thoughts - The report suggests that the innovative drug sector has undergone sufficient adjustment and is expected to rebound post-Q3 reports. The focus should be on high-performing sectors and companies with strong earnings capabilities [5][6]. - The report recommends a combination of innovative drugs, CXO, and medical devices for medium to long-term investment strategies, emphasizing the need for strategic allocation in high-growth areas [5][6].